Bain Capital Life Sciences Investors’s Nurix Therapeutics NRIX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,132,397	Closed	-$16.6M	–	27
2024 Q1	$16.6M	Sell	1,132,397 -690,486	-38%	-$7.43M	1.34%	16
2023 Q4	$18.8M	Hold	1,822,883	–	–	1.8%	15
2023 Q3	$14.3M	Hold	1,822,883	–	–	1.6%	15
2023 Q2	$18.2M	Hold	1,822,883	–	–	1.88%	18
2023 Q1	$16.2M	Hold	1,822,883	–	–	2.02%	17
2022 Q4	$20M	Hold	1,822,883	–	–	2.24%	15
2022 Q3	$23.8M	Hold	1,822,883	–	–	2.84%	13
2022 Q2	$23.1M	Buy	1,822,883 +538,570	+42%	+$6.1M	2.71%	12
2022 Q1	$18M	Hold	1,284,313	–	–	1.75%	15
2021 Q4	$37.2M	Sell	1,284,313 -1	-0%	-$30	2.95%	12
2021 Q3	$38.5M	Hold	1,284,314	–	–	2.39%	12
2021 Q2	$34.1M	Hold	1,284,314	–	–	2.23%	10
2021 Q1	$39.9M	Hold	1,284,314	–	–	2.26%	12
2020 Q4	$42.2M	Hold	1,284,314	–	–	2.65%	11
2020 Q3	$44.8M	Buy	+1,284,314	New	+$32.4M	4.18%	8

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bain Capital Life Sciences Investors's NRIX Position: Q2 2024 in Review

Bain Capital Life Sciences Investors sold out of Nurix Therapeutics (NRIX) in Q2 2024, closing a stake of 1,132,397 shares — an estimated $16.6M sold.

Bain Capital Life Sciences Investors first reported a position in NRIX in Q3 2020 and held it in 15 quarters. The position peaked at $44.8M in Q3 2020. 173 funds tracked by Wall St. Rank hold NRIX as of Q2 2024.

Bain Capital Life Sciences Investors reported no remaining Nurix Therapeutics position as of Q2 2024 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 1,132,397 Nurix Therapeutics shares in Q2 2024, an estimated $16.6M.
Bain Capital Life Sciences Investors first reported a position in Nurix Therapeutics in Q3 2020 and held it in 15 quarters.
Bain Capital Life Sciences Investors's Nurix Therapeutics position peaked at $44.8M in Q3 2020.
173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2024.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2024, filed 12 Aug 2024.